{"id":551042,"date":"2021-07-02T17:30:02","date_gmt":"2021-07-02T17:30:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=551042"},"modified":"2021-07-02T17:30:02","modified_gmt":"2021-07-02T17:30:02","slug":"fragile-x-syndrome-fxs-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/fragile-x-syndrome-fxs-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast_551042.html","title":{"rendered":"Fragile X Syndrome (FXS) Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast"},"content":{"rendered":"
\"Fragile<\/a><\/p>\n
\n
Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Fragile X Syndrome (FXS) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Fragile X Syndrome (FXS) Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

Fragile X Syndrome (FXS) is a genetic disease due to a CGG trinucleotide expansion, named full mutation (greater than 200 CGG repeats), in the fragile X mental retardation 1 gene locus Xq27.3. It leads to a hypermethylated region in the gene promoter, therefore, silencing it and lowering the expression levels of the fragile X mental retardation 1, a protein involved in synaptic plasticity and maturation. Also, FXS is considered the most common inherited cause of intellectual disability and the second most prevalent cause after Down syndrome.<\/p>\n

At birth FXS neonates often exhibit no clinical signs of FXS with most parameters (e.g., head circumference, weight, and height) in the normal range. In early childhood FXS, physical and developmental features become more apparent, including developmental delays, psychomotor delays, intellectual disabilities, and a long face with prominent ears and flat feet. The behavioral phenotype of FXS includes significant anxiety, attention deficit hyperactivity disorder (ADHD), and hyperarousal to sensory stimuli.<\/p>\n

There is no single treatment for FXS, but some treatments help minimize the symptoms of the condition. The treatment regimen of FXS includes the use of stimulants, selective serotonin reuptake inhibitors (SSRIs), atypical antipsychotics, and alpha agonists.<\/strong><\/em><\/p>\n

The market is expected to grow by the factors like the expected entry of emerging therapies with novel targets and pricing. Furthermore, the impending products such as Zygel, Acamprosate, BPN14770, OV101, and Trofinetide are anticipated to expand the market with more penetration in the 7MM markets.<\/p>\n

Get FREE sample copy at: https:\/\/www.delveinsight.com\/sample-request\/fragile-x-syndrome-fxs-market<\/a><\/strong><\/em><\/p>\n

The Fragile X Syndrome (FXS) Market Research Report<\/strong> covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Fragile X Syndrome (FXS) market Size from 2017 to 2030 segmented by seven major markets. <\/p>\n

The report provides a detailed current Fragile X Syndrome (FXS) treatment practice\/algorithm<\/strong>, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

 <\/p>\n

\"Fragile<\/p>\n

Fragile X Syndrome (FXS) Market Key Facts<\/strong><\/p>\n